44 results about "High intraocular pressure" patented technology

The invention discloses a small vision detection device for eye examination, and particularly relates to the technical field of vision detection devices.The small vision detection device comprises a device bottom plate, a vision detection mechanism is arranged at the top of the device bottom plate and comprises a first moving plate, and the first moving plate is arranged at the top of the device bottom plate; the top of the first moving plate is fixedly connected with a moving mounting plate, and a display screen is mounted on the front side of the moving mounting plate. By arranging the vision detection mechanism and the adjusting mechanism, the comprehensiveness of vision detection is improved, the vision definition is detected, the type and degree of refractive errors such as myopia, hyperopia and astigmatism can be accurately diagnosed through a diopter test, whether a vision problem exists or not is determined, and the vision detection accuracy is improved. Meanwhile, some eye diseases possibly influencing vision can be indirectly found through intraocular pressure testing, retina injury and vision loss caused by too high intraocular pressure can be prevented by monitoring changes of the intraocular pressure, the examination effect is good, and vision detection is more comprehensive.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention relates to the technical field of animal disease models, and discloses a construction method of an intraocular hypertension animal model, comprising the following steps: step A, selecting an experimental animal; step B, preparing experimental instruments and reagents; c, in an anesthesia mode, deep anesthesia is carried out on the animal, and subsequent deep anesthesia is carried out; d, intraocular pressure measurement, wherein the basic intraocular pressure value is measured through anterior chamber injection. Step E, performing anterior chamber injection, and using ofloxacin antibiotic oculentum to prevent infection after an operation; and F, intraocular pressure measurement: measuring the change of the intraocular pressure value after the anterior chamber injection. According to the method, the natural pathological process of open-angle glaucoma is simulated by injecting IFN-beta into the anterior chamber, the situation that acute intraocular pressure rise is caused mainly by blocking an aqueous humor flow outlet channel like other models is avoided, and the method can better reflect the real situation of glaucoma diseases; in addition, the model avoids intraocular pressure change caused by anatomical structure change, so that the accuracy and reliability of the model are improved.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

The invention relates to the technical field of medical apparatus and instruments, in particular to an intraoperative viscoelastic agent suction instrument for intraocular lens implantation, which comprises a replacement host, a liquid supply pump, a suction pump and a controller electrically connected with the liquid supply pump and the suction pump, the replacement main machine is further provided with a liquid inlet and a liquid outlet which are communicated with the liquid supply pump, and a suction port and a liquid discharge port which are communicated with the suction pump. An input connector and an output connector are arranged at one end of the handle, a replacement pipe is arranged at the other end of the handle, a liquid adding hole and a suction hole are formed in the free end of the replacement pipe, the liquid adding hole is communicated with the input connector, and the suction hole is communicated with the output connector. By balancing perfusion and suction amounts, intraoperative intraocular pressure fluctuation is avoided, intraoperative intraocular pressure caused by high intraocular pressure or intraocular pressure caused by excessive suction is avoided, and therefore the risk of optic nerve or retina injury is reduced.

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The application provides a use of a combination of metoclopramide and latanoprost for preparing an anticoagulant drug, and belongs to the technical field of biological medicines. It is accidentally found that the anticoagulant effect of patients with deep vein thrombosis combined with high intraocular pressure is improved after long-term continuous oral administration of metoclopramide. Thanks to this beneficial discovery, the application realizes good anticoagulant effect by applying the latanoprost liniment in a topical manner on the basis of oral administration of metoclopramide. The application is convenient to administer, has definite and sustained curative effect, and is safe and reliable. The application expands the optional range of anticoagulant drugs, and realizes better curative effect at the same time, and has outstanding technical advantages and wide popularization prospect.

The invention relates to the technical field of biological medicines, and particularly provides a preparation method of chiral cadmium selenide quantum dots and application of the chiral cadmium selenide quantum dots in retinal degeneration. The chiral cadmium selenide quantum dot with high efficiency is successfully synthesized by accurately controlling reaction conditions. The chiral cadmium selenide quantum dot has a remarkable protection effect on retinal injury caused by intraocular hypertension or oxidative stress, and can effectively improve the survival rate of retinal ganglion cells and relieve pathological changes of retina. In a rat model, a local point-to-eye administration mode shows a good treatment effect and biological safety. The invention provides a new thought and means for treatment of retinal degeneration, and has a wide clinical application prospect. In addition, the preparation method of the quantum dot and the compound thereof is simple and convenient, the cost is relatively low, and a new possibility is provided for expanding the application of the quantum dot in the field of biomedicine.

Cationic nanoparticles loaded with prostaglandins, and their preparation methods and applications. Prostaglandin-loaded lignin nanoparticles were prepared by nanoprecipitation method, and chitosan oligosaccharides or their derivatives were modified on the surface by electrostatic action. The particle size and surface charge of the nanoparticles were studied in detail by DLS, and the low cytotoxicity of the nanoparticles was confirmed by the CCK-8 method. The good in vivo safety was further verified by eye drops in animals for 14 days. It was also verified that cationic nanoparticles can prolong the ocular surface retention time of model drugs and reduce the expression of ZO-1. In the dexamethasone-induced high intraocular pressure model, the drug-loaded cationic nano eye drops achieved an intraocular pressure-lowering effect that was superior to naked drugs and anionic nano drugs. These nanoparticles are a new and efficient ocular drug delivery carrier with both long-term retention and ocular surface penetration.

The present invention discloses a microporous drainage device for ophthalmic surgery and a delivery system thereof. The drainage device comprises a drainage valve body, and the drainage valve body comprises a fixed portion, a first drainage portion and a second drainage portion; the first drainage portion is arranged on one side of the fixed portion, and is used to insert a capillary tube into the anterior chamber of the patient's eyeball; the second drainage portion is arranged on the other side of the fixed portion opposite to the first drainage portion, and is used to connect with the capillary tube of the patient's eyeball vein; and a microporous drainage channel is arranged on the drainage valve body. The delivery system of the microporous drainage device for ophthalmic surgery comprises a hollow hand-held rod, and an operating head and a wire drawing rod are respectively arranged at both ends of the hand-held rod. Sutures are passed through the hand-held rod, and the sutures have a closed loop portion and a wire drawing portion. The closed loop portion is embedded in the operating head, and the wire drawing portion is fixed to the wire drawing rod. The microporous drainage device for ophthalmic surgery of the present invention can solve the problem of high intraocular pressure in glaucoma, and at the same time avoid various inflammatory problems caused by the implantation of commonly used drainage valves, thereby safely and efficiently treating glaucoma.

The invention discloses an intraocular pressure monitoring device and a control method thereof, and the intraocular pressure monitoring device comprises a probe which is arranged along the axis of the intraocular pressure monitoring device; the sensing elements are distributed on a circular ring surrounding the probe at intervals, the circle center of the circular ring is located on the axis, and the plane where the circular ring is located is perpendicular to the axis; each sensing element is used for transmitting a charge signal to the cornea and receiving a first sensing signal generated by charges gathered at the center of the cornea; the main control device is in signal connection with the sensing elements, is used for controlling the sensing elements to independently emit charge signals according to different time sequences, and is also used for acquiring distance information between the sensing elements and the cornea center according to the first sensing signal; and when the distance information represents that the distance between each sensing element and the cornea center is equal, the probe is determined to be in an alignment state, so that the judgment result is more accurate, the detection accuracy and accurate measurement precision of the intraocular pressure monitoring device are improved, and the use convenience is improved.

The application provides a medical atomization eyeshade, which comprises an eye covering mechanism, a head fixing object and a heat alternating mechanism. The eye covering mechanism is used for covering the eyes of a patient. The head fixing object is arranged on the outer surface of the eye covering mechanism and is used for fixing and limiting the position of the eye covering mechanism in cooperation with the head of the patient. The heat alternating mechanism is arranged on the outer surface of the eye covering mechanism and is in communication with the inside of the eye covering mechanism. The medicine outside is introduced into the inside of the eye covering mechanism through the heat alternating mechanism and contacts the eyes of the patient. In use, the heat alternating mechanism intermittently heats and stops heating the atomized medicine according to the setting during the process that the atomized medicine is introduced into the inside of the eye covering mechanism through the heat alternating mechanism, so that the medicine generates cold-heat alternation, the circulation of the eyes is promoted through the cold-heat alternating medicine, and the symptoms of high intraocular pressure are reduced or alleviated.

The application belongs to the field of intraocular pressure measurement, and discloses a portable LC wireless intraocular pressure sensor signal acquisition device and application thereof. The device comprises: an intraocular pressure acquisition impedance module for continuously collecting intraocular pressure data signals and generating inductive coupling; a signal conditioning circuit for generating and transmitting amplified sweep signals of different frequencies to the intraocular pressure acquisition impedance module to cause inductive coupling of the intraocular pressure acquisition impedance module, so that the impedance of the intraocular pressure acquisition impedance module changes, and the amplitude ratio and phase difference of the intraocular pressure data signals collected after the impedance changes are detected and analog-to-digital converted; a control circuit for receiving the amplitude ratio and phase difference after analog-to-digital conversion, calculating the impedance real part value, and obtaining the impedance real part curve of the intraocular pressure acquisition impedance module and the resonant frequency at the peak value; and a power supply module for supplying power to the signal conditioning circuit and the control circuit. The application can improve the accuracy and convenience of intraocular pressure measurement.

The application relates to an intraocular pressure measuring method and an intraocular pressure measuring system, wherein the intraocular pressure measuring method comprises the following steps: judging whether a corneal contact lens provided with a magnetic component deviates from an intraocular pressure measuring position according to a detected magnetic field feature in a detected intraocular pressure measuring area, wherein the intraocular pressure measuring position is located in the intraocular pressure measuring area; in the case that the corneal contact lens deviates from the intraocular pressure measuring position, correcting the position of the corneal contact lens based on the magnetic field feature, so that the corneal contact lens is located at the intraocular pressure measuring position; and finally, measuring the intraocular pressure through the corneal contact lens located at the intraocular pressure measuring position. The position detection and position correction of the corneal contact lens can be realized, so that the corneal contact lens is located at an accurate intraocular pressure measuring position before intraocular pressure measurement, and the success rate of intraocular pressure measurement is improved.

The utility model belongs to the field of medical instruments, and particularly relates to a glaucoma hypertension intraocular pressure drainage device which comprises a tunnel knife used for manufacturing a sclera tunnel and an I-shaped drainage valve used for draining aqueous humor to reduce intraocular pressure, and the tunnel knife comprises a knife head and a knife handle arranged at the tail end of the knife head; a storage groove used for containing the I-shaped drainage valve is formed in the knife handle. A pipe cavity is formed in the I-shaped drainage valve in the length direction of the I-shaped drainage valve and penetrates through the I-shaped drainage valve. The tunnel knife can be used for accurately manufacturing a sclera tunnel with the length of 4mm and the width of 3mm, and the I-shaped drainage valve made of silica gel can be folded and can be implanted into the sclera tunnel through the injector. A tube cavity with the inner diameter being 60 micrometers is formed in the I-shaped drainage valve, aqueous humor can be drained to the position below the conjunctiva through the tube cavity in the drainage valve, intraocular pressure is reduced, damage of intraocular hypertension to eyes is reduced, the I-shaped drainage valve does not need to be fixed through suture, and the drainage device is simple, efficient, accurate and suitable for wide popularization.

The invention relates to the technical field of biology, in particular to a method for constructing an intraocular hypertension model through anterior chamber injection of GMA-EPL-LAP hydrogel. The construction method of the chronic intraocular hypertension animal model is high in stability and more suitable for long-term observation and research, the problem that the model is poor in stability is solved, the intraocular hypertension maintaining time is greatly prolonged, and the risk that intraocular pressure is increased due to repeated injection after the intraocular pressure is reduced is reduced; operation is easy and convenient, complex instruments and technologies are not needed, and harm to animals can be reduced; the application range is wide; and the hydrogel can be gradually degraded and absorbed in vivo, so that the potential safety hazard caused by long-term implantation of the hydrogel in vivo is avoided.

The invention provides a pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a compound of formula I. The pharmaceutical composition provided by the invention has high drug loading capacity, good uniformity and good stability, and can be used for preparing drugs for preventing and / or treating glaucoma or intraocular hypertension. # imgabs0 #

The invention provides application of tanshinone IIA in a carbonic anhydrase inhibitor and a product, and belongs to the field of medicines. According to the application of the tanshinone IIA in the carbonic anhydrase inhibitor, the tanshinone IIA can be combined with carbonic anhydrase to inhibit the activity of the carbonic anhydrase, and the tanshinone IIA can be used in drugs for reducing intraocular pressure, inducing diuresis, correcting metabolic acid / alkali poisoning, increasing vascular oxygen flux, improving pulmonary ventilation, expanding cerebral vessels, inducing tumor cell apoptosis or inhibiting osteoclast bone resorption. The carbonic anhydrase inhibitor can be used for treating carbonic anhydrase-related cardiovascular diseases, altitude sickness, ocular diseases with intraocular hypertension as symptoms, osteoporosis or diseases caused by reduction of bone mineral density, inducing diuresis or correcting metabolic acid / alkali poisoning, and provides reference for design and drug research and development of novel carbonic anhydrase inhibitors. Carbonic anhydrase inhibition drugs with smaller side effects and better curative effects are expected to be developed.

The application discloses a method for establishing an angle-closure glaucoma animal model. The method comprises the following steps: performing mydriasis on an eye of an animal model after general anesthesia, performing local anesthesia on an eye surface of the model eye after 10 minutes; after the pupil of the model eye is reduced, eye gel is added to the eye surface; a semiconductor laser is used to uniformly hit a plurality of laser points at an iris margin; and eye drops are added to the eye surface after laser treatment. The method uses a 532nm laser to hit the iris margin, causes local edema of the iris margin, narrows a passage through which aqueous humor flows from the posterior chamber into the anterior chamber, and increases the pressure of the posterior chamber. The method can keep the high intraocular pressure of the established angle-closure glaucoma animal model between 20-30mmHg, the success rate is 70%, the high intraocular pressure can be maintained for more than one week, no wound is caused on the eye of the animal model, there is no inflammatory reaction on the eye surface, the cornea has no edema and new blood vessels, and the operation of the model can be completed within 10 minutes.

This invention relates to the field of biomedical technology, specifically proposing a method for preparing chiral cadmium selenide quantum dots and their application in retinal degeneration. By precisely controlling the reaction conditions, highly efficient chiral cadmium selenide quantum dots were successfully synthesized. The chiral cadmium selenide quantum dots of this invention exhibit significant protective effects against retinal damage caused by high intraocular pressure or oxidative stress, effectively improving the survival rate of retinal ganglion cells and alleviating retinal pathological changes. In a rat model, topical ocular administration demonstrated good therapeutic efficacy and biosafety. This invention provides new ideas and methods for the treatment of retinal degeneration and has broad clinical application prospects. Furthermore, the preparation method of these quantum dots and their complexes is simple and low-cost, providing new possibilities for expanding the application of quantum dots in the biomedical field.

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

The invention relates to the technical field of biological medicine, in particular to application of a ferroptosis inhibitor in preparation of a medicine for preventing and treating intraocular hypertension. Research finds that the ferroptosis inhibitor can effectively slow down fibrosis of trabecular meshwork cells caused by SiO, and evidence and thought are provided for treating intraocular hypertension caused by SiO filling.

The utility model discloses a compressing device used after glaucoma operation. The compressing device comprises a head sleeve, a compressing piece and an adjusting assembly. The head sleeve can be fixed to the head in a sleeving mode and comprises an arc-shaped strip and a connecting band, the two ends of the arc-shaped strip are connected through the connecting band, and the length of the connecting band can be adjusted. The pressing piece is located on the inner side, facing the human body, of the head sleeve and used for pressing the eyes; the adjusting assembly is arranged in the radial direction of the head sleeve and used for connecting the pressing piece with the arc-shaped strip, and the length of the adjusting assembly is adjustable. According to the compression device after the glaucoma operation, pressure can be conveniently applied to eyes after the glaucoma operation, so that intraocular pressure is improved.

Provided herein are compounds comprising a formula of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl adamantane carboxylate (e.g., compounds of formula (I) or formula (II)) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension.

The present invention relates to a nitric oxide releasing type 5 phosphodiesterase (PDE5) inhibitor of formula (I) or (Ib) or (II), or a stereoisomer or a pharmaceutically acceptable salt thereof, which is useful in the treatment of ocular conditions associated with elevated intraocular pressure, such as ocular hypertension, glaucoma or retinopathy. The invention further relates to 3-[(2S)-2, 3-bis (nitrooxy) propoxy] propionic acid and 6-(nitrooxy) hexanoic acid for use in the treatment of ocular conditions associated with elevated intraocular pressure, such as ocular hypertension, glaucoma or retinopathy. # imgabs0 #

The invention discloses a springback type tonometer and an intraocular pressure measuring method. Wherein the tonometer comprises a tonometer main body, and the tonometer main body comprises a probe, a driving coil and a measuring coil; a power regulation module; the controller is used for executing the following operations: adjusting the first excitation voltage through the power adjusting module; obtaining a first corresponding relation; determining an actually measured parameter value by using the first corresponding relation through the controller; under the condition that the difference value between the measured parameter value and the target parameter value is greater than a preset threshold value, calculating a correction voltage by using the difference value; correcting the first excitation voltage according to the correction voltage to obtain a target excitation voltage; when the difference value between the measured parameter value and the target parameter value is smaller than or equal to a preset threshold value, determining the first excitation voltage as a target excitation voltage; and measuring the intraocular pressure of the to-be-measured object according to the target excitation voltage to obtain an output intraocular pressure value. According to the embodiment of the invention, the accuracy of intraocular pressure measurement can be improved, and more comfortable use experience is brought to a user.

The invention relates to an intraocular pressure measuring method and an intraocular pressure measuring system.The intraocular pressure measuring method comprises the steps that whether a corneal contact lens provided with a magnetic component deviates from an intraocular pressure measuring position or not is judged according to detected magnetic field characteristics detected in an intraocular pressure measuring area, and the intraocular pressure measuring position is located in the intraocular pressure measuring area; under the condition that the corneal contact lens deviates from the intraocular pressure measurement position, position correction is conducted on the corneal contact lens based on the magnetic field characteristics, so that the corneal contact lens is located at the intraocular pressure measurement position; and finally, the intraocular pressure is measured through the cornea contact lens at the intraocular pressure measuring position. Position detection and position correction of the corneal contact lens can be realized, so that the corneal contact lens is positioned at an accurate intraocular pressure measurement position before intraocular pressure measurement, and the success rate of intraocular pressure measurement is improved.

The application discloses a method for constructing a glaucoma intervention disease model, and relates to the field of glaucoma research. The MAdCAM of a non-human target mammal is not expressed or is inhibited, and thus the animal model constructed does not itself show glaucoma phenotypes such as damage or loss of ganglion cells. A new glaucoma animal model can be obtained by inducing high intraocular pressure of the animal. Compared with a wild-type high intraocular pressure model, the new glaucoma animal model has reduced damage of retinal ganglion cells, and the loss of ganglion cells in different regions of the retina is obviously reduced, the glaucoma symptoms are relieved, and the glaucoma course is delayed. It is indicated that the model can be used for related research on glaucoma diseases, and especially provides an animal model basis and research reference for research on the pathogenesis and intervention strategies of glaucoma. In addition, the glaucoma intervention animal model provided by the application can be used for research on retinal ganglion cell nerve damage.